Announcements Trials
Browse Landscape

Phase

Phase NA 4Phase 3 1Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 424Carcinoma, Non-Small-Cell Lung 92Neoplasm Metastasis 69Neoplasms 60Carcinoma, Renal Cell 54Lymphoma, T-Cell, Cutaneous 52Ovarian Neoplasms 46Squamous Cell Carcinoma of Head and Neck 42Breast Neoplasms 40Colorectal Neoplasms 38Stomach Neoplasms 37Skin Neoplasms 35Lymphoma 32Mycosis Fungoides 31Carcinoma, Merkel Cell 31Uveal Melanoma 30Triple Negative Breast Neoplasms 29Lung Neoplasms 29Sezary Syndrome 28Lymphoma, Non-Hodgkin 28Lymphoma, Follicular 27Hodgkin Disease 27Pancreatic Neoplasms 26Uterine Cervical Neoplasms 25Sarcoma 25Lymphoma, Large B-Cell, Diffuse 24Leukemia, Lymphocytic, Chronic, B-Cell 24Lymphoma, B-Cell, Marginal Zone 23Carcinoma, Hepatocellular 23Lymphoma, Mantle-Cell 22

Interventions

Palonosetron 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Nausea × Dermatologic × Clear all
NCT00412425 2012-05-04

Palonosetron for Prevention of Biochemotherapy Induced Nausea and Vomiting

M.D. Anderson Cancer Center

Phase 1/2 Completed
30 enrolled 4 charts
Dermatologic

Anorexia, Melanoma, Nausea, Vomiting, Weight Loss

Data powered by HemOnc (CC BY 4.0) Colophon âš¡